Regulation of sarcoplasmic reticulum Ca2+-ATPase and phospholamban in the failing and nonfailing heart

Cardiovascular Research

Volumn 45, Issue 1, 2000, Pages 245-252

  Ravens, U ^a   Dobrev, D ^a  

^a UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

Author keywords

Calcium (cellular); Genetic code; Heart failure; SR (function); Ventricular function

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); MESSENGER RNA; PHOSPHOLAMBAN;

ENZYME ACTIVITY; GENE EXPRESSION; HEART CONTRACTION; HEART EXCITATION; HEART FAILURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA ANALYSIS; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM-BINDING PROTEINS; GENE EXPRESSION REGULATION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; REFERENCE VALUES; SARCOPLASMIC RETICULUM;

EID: 0033991287     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00338-7     Document Type: Review

References (106)

1. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res. 31:1996;625-632.
2. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res. 37:1998;279-289.
3. 2+ currents in compensated hypertrophy and heart failure. Cardiovasc Res. 37:1998;300-311.
4. Näbauer M., Kääb S. Potassium channel down-regulation in heart failure. Cardiovasc Res. 37:1998;324-334.
5. Phillips R.M., Narayan P., Gómez A.M., et al. Sarcoplasmic reticulum in heart failure: central player or bystander? Cardiovasc Res. 37:1998;346-351.
6. De Tombe P.P. Altered contractile function in heart failure. Cardiovasc Res. 37:1998;367-380.
7. Schaub M.C., Hefti M.A., Zuellig R.A., Morano I. Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc Res. 37:1998;381-404.
8. Bers D.M. Excitation-contraction coupling and cardiac contractile force. 1991;Kluwer, Dodrecht, Boston, London.
9. i during caffeine contractures in rabbit cardiomyocytes. J Physiol (Lond). 453:1992;581-608.
10. 2+ transients during the contractile cycle in adult rabbit cardiac myocytes. Biochem Biophys Res Commun. 236:1997;738-742.
11. Gwathmey J.K., Slawsky M.T., Hajjar R.J., Briggs G.M., Morgan J.P. Role of intracellular calcium handling in force-interval relationship of human ventricular myocardium. J Clin Invest. 85:1990;1599-1613.
12. Ohler A., Ravens U. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther. 270:1994;460-465.
13. Gwathmey J.K., Warren S.E., Briggs G.M., et al. Diastolic dysfuntion in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest. 87:1991;1023-1031.
14. Morgan J.P. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. New Engl J Med. 325:1991;625-632.
15. Beuckelmann D.J., Näbauer M., Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 85:1992;1046-1055.
16. Mulieri L.A., Hasenfuss G., Leavitt B., Allen P.D., Alpert N.R. Altered myocardial force-frequency relation in human heart failure. Circulation. 85:1992;1743-1750.
17. Schwinger R.H.G., Böhm M., Erdmann E. Inotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy. Am Heart J. 123:1992;116-123.
18. Gwathmey J.K., Copelas L., MacKinnon R., et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 61:1987;70-76.
19. Simmerman H.K.B., Jones L.R. Phospholamban: protein structure, mechanism of action and role in cardiac function. Physiol Rev. 78:1998;921-947.
20. 2+ pump. J Biol Chem. 264:1989;18561-18568.
21. Dillmann W.H. Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Mol Cell Biochem. 157:1996;125-128.
22. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 100:1997;380-389.
23. 2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res. 83:1998;1205-1214.
24. 2+-ATPase. Circ Res. 83:1998;889-897.
25. 2+ pump of sarcoplasmic reticulum. Nature. 342:1989;90-92.
26. Voss J., Jones L.R., Thomas D.D. The physical mechanism of calcium pump regulation in the heart. Biophys J. 67:1994;190-196.
27. Hasenfuss G., Meyer M., Schillinger W., et al. Calcium handling proteins in the failing human heart. Basic Res Cardiol. 92:1997;87-93.
28. Luo W., Grupp I.L., Harrer J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res. 75:1994;401-409.
29. 2+/calmodulin-dependent phosphorylation or by interaction with phospholamban. J Biol Chem. 271:1996;14206-14231.
30. 2+-ATPases in the cardiovascular system during growth and proliferation. Trends Cardiovasc Med. 8:1998;75-82.
31. Chu G., Luo W., Slack J.P., et al. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ Res. 79:1996;1064-1076.
32. Li L., Chu G., Kranias E.G., Bers D.M. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol. 274:1998;H1335-H1347.
33. i transients in phospholamban-deficient mouse ventricular cells. Am J Physiol. 274:1998;H1800-H1811.
34. Kadambi V.J., Ponniah S., Harrer J.M., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 97:1996;533-539.
35. Anderson P.A., Malouf N.N., Oakeley A.E., Pagani E.D., Allen P.D. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res. 69:1991;1226-1233.
36. Lowes B.D., Minobe W., Abraham W.T., et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 100:1997;2315-2324.
37. Nakao K., Minobe W., Roden R., Bristow M.R., Leinwand L.A. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 100:1997;2362-2370.
38. James J., Robbins J. Molecular remodeling of cardiac contractile function. Am J Physiol. 273:1997;H2105-H2118.
39. Arai M., Alpert N.R., Maclennan D.H., Barton P., Periasamy M. Alterations in sarcoplasmic gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res. 72:1993;463-469.
40. 2+-exchanger in end-stage human heart failure. Circ Res. 75:1994;443-453.
41. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 43:1991;203-242.
42. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res. 39:1998;60-76.
43. 2+-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem. 163-164:1996;285-290.
44. 2+-ATPase activity and expression in ventricular myocardium of dogs with heart failure. Am J Physiol. 273:1997;H12-H18.
45. Yue P., Long C.S., Austin R., et al. Post-infarction heart failure in the rat is associated with distinct alterations in cardiac myocytes molecular phenotype. J Mol Cell Cardiol. 30:1998;1615-1630.
46. Simonini A., Chang K., Yue P., Long C.S., Massie B.M. Expression of skeletal muscle sarcoplasmic reticulum calcium-ATPase is reduced in rats with postinfarction heart failure. Heart. 81:1999;303-307.
47. Williams R.E., Kass D.A., Kawagoe Y., et al. Endomyocardial gene expression during development of pacing tachycardia-induced heart failure in the dog. Circ Res. 75:1994;615-623.
48. 2+ ATPase gene expression in congestive heart failure: effect of chronic norepinephrine infusion. J Mol Cell Cardiol. 30:1998;175-185.
49. 2+ homeostasis in rabbits with pacing-induced heart failure. Am J Physiol. 275:1998;H1441-H1448.
50. 2+-ATPase in contractile dysfunction of myocytes in tachycardia-induced heart failure. Am J Physiol. 275:1998;H31-H40.
51. O'Rourke B., Kass D.A., Tomaselli G.F., et al. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure. I: experimental studies. Circ Res. 83:1999;562-570.
52. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res. 77:1996;759-764.
53. Zarain-Herzberg A., Rupp H., Elimban V., Dhalla N.S. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J. 10:1996;1303-1309.
54. 2+ ATPase during progression of left ventricular hypertrophy. Am J Physiol. 272:1997;H2416-H2424.
55. McCall E., Ginsburg K.S., Bassani R.A., et al. Ca flux, contractility, and excitation-contraction coupling in hypertrophic rat ventricular myocytes. Am J Physiol. 274:1998;H1348-H1360.
56. Cadre B.M., Qi M., Eble D.M., et al. Cyclic stretch down-regulates calcium transporter gene expression in neonatal rat ventricular myocytes. J Mol Cell Cardiol. 30:1998;2247-2259.
57. LekanneDeprez R.H., van den Hoff M.J., de Boer P.A., et al. Changing patterns of gene expression in the pulmonary trunk-banded rat heart. J Mol Cell Cardiol. 30:1998;1877-1888.
58. 2+-ATPase gene. Circ Res. 71:1992;9-17.
59. Tajima M., Weinberg E.O., Bartunek J., et al. Treatment with growth hormone enhances contractile reverse and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation. 99:1999;127-134.
60. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 85:1990;305-309.
61. Takeishi Y., Bhagwat A., Ball N.A., et al. Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol. 276:1999;H53-H62.
62. Arai M., Matsui H., Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res. 74:1994;555-564.
63. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 92:1995;3220-3228.
64. 2+ ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med. 74:1996;321-332.
65. Mittmann C., Munstermann U., Weil J., et al. Analysis of gene expression patterns in small amounts of human ventricular myocardium by a multiplex RNase protection assay. J Mol Med. 76:1998;133-140.
66. Feldman A.M., Ray P.E., Silan C.M., et al. Selective gene expression in failing human heart. Quantification of steady-state levels of messenger RNA in endomyocardial biopsies using the polymerase chain reaction. Circulation. 83:1991;1866-1872.
67. 2+-ATPase in failing and nonfailing myocardium. Circ Res. 75:1994;434-442.
68. Hasenfuss G., Reinecke H., Studer R., et al. Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol. 91:1996;17-22.
69. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation. 99:1999;641-648.
70. Meyer M., Schillinger W., Pieske B., et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 92:1995;778-784.
71. 2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation. 90:1994;653-657.
72. Böhm M., Reiger B., Schwinger R.H., Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res. 28:1994;1713-1719.
73. Schmidt U., Hajjar R.J., Helm P.A., et al. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol. 30:1998;1929-1937.
74. Frank K., Bolck B., Bavendiek U., Schwinger R.H. Frequency dependent force generation correlates with sarcoplasmic calcium ATPase activity in human myocardium. Basic Res Cardiol. 93:1998;405-411.
75. Sainte Beuve C., Allen P.D., Dambrin G., et al. Cardiac calcium release channel (ryanodine receptor) in control and cardiomyopathic human hearts: mRNA and protein contents are differentially regulated. J Mol Cell Cardiol. 29:1997;1237-1246.
76. Koss K.L., Grupp I.L., Kranias E.G. The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic Res Cardiol. 92:1997;17-24.
77. 2+-ATPase. Circ Res. 81:1997;145-153.
78. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. New Engl J Med. 307:1982;205-211.
79. 1-adrenergic receptors in the failing human heart. Circulation. 87:1993;454-463.
80. De la Bastie D., Levitsky D., Rappaport L., et al. Function of the sarcoplasmic reticulum and expression of its Ca2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res. 66:1990;554-564.
81. 2+ pump ATPase activity in congestive heart failure due to myocardial infarction. Can J Cardiol. 12:1996;1065-1073.
82. 2+-pump ATPase activity in tachycardia heart failure. Cell Calcium. 16:1994;349-356.
83. Bavendiek U., Brixius K., Munch G., et al. Effect of inotropic interventions on the force-frequency relation in the human heart. Basic Res Cardiol. 93:1998;76-85.
84. 2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res. 65:1989;1141-1144.
85. 2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J Clin Invest. 85:1990;1698-1702.
86. Feldman M.D., Gwathmey J.K., Phillips P., Schoen F., Morgan J.P. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol. 3:1988;273-283.
87. Hasenfuss G., Holubarsch C., Hermann H.-P., et al. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J. 15:1994;164-170.
88. Davies C.H., Davia K., Bennett J.G., et al. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 92:1995;2540-2549.
89. Pieske B., Kretschmann B., Meyer M., et al. Alteration in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation. 92:1995;1169-1178.
90. Ravens U., Davia K., Davies C.H., et al. Tachycardia-induced failure alters contractile properties of canine ventricular myocytes. Cardiovasc Res. 32:1996;613-621.
91. Neumann T., Ravens U., Heusch G. Characterization of excitation-contraction coupling in conscious dogs with pacing-induced heart failure. Cardiovasc Res. 37:1998;456-466.
92. Bristow M.R. Why does the myocardium fail? Insights from basic science. Lancet. 352:1998;SI8-SI14.
93. Mukherjee R., Spinale F.G. L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. J Mol Cell Cardiol. 30:1998;1899-1916.
94. Shorofsky S.R., Aggarwal R., Corretti M., et al. Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Circ Res. 84:1999;424-434.
95. Mewes T., Ravens U. L-type calcium currents of human myocytes from ventricle of non-failing and failing hearts and from atria. J Mol Cell Cardiol. 26:1994;1307-1320.
96. Ouadid H., Albat B., Nargeot J. Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol. 25:1995;282-291.
97. Piot C., Lemaire S., Albat B., et al. High frequency-induced upregulation of human cardiac calcium currents. Circulation. 93:1996;120-128.
98. Gomez A.M., Valdivia H.H., Cheng H., et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 276:1997;800-806.
99. Sharov V.G., Goussev A., Lesch M., Goldstein S., Sabbah H.N. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 30:1998;1757-1762.
100. Pérez N.G., Hashimoto K., McCune S., Altschuld R.A., Marbán E. Origin of contractile dysfunction in heart failure. Calcium cycling versus myofilaments. Circulation. 99:1999;1077-1083.
101. Wolff M.R., Buck S.H., Stoker S.W., Greaser M.L., Mentzer R.M. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest. 98:1996;167-176.
102. Rüegg J.C., Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol. 14:(3):1989;S20-S23.
103. De Tombe P.P., Wannenburg T., Fan D.S., Little W.C. Right ventricular contractile protein function in rats with left ventricular myocardial infarction. Am J Physiol. 271:1996;H73-H79.
104. Li Q., Li B.S., Wang X.W., et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 100:1997;1991-1999.
105. Feuerstein G., Ruffolo R.R. Jr., Yue T.-L. Apoptosis and congestive heart failure. Trends Cardiovasc Med. 7:1997;249-255.
106. Haunstetter A., Izumo S. Apoptosis. Basic mechanisms and implications for cardiovascular disease. Circ Res. 82:1998;1111-1129.